These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. [Thalidomide and thrombosis]. Schmutz JL; Barbaud A; Trechot P Ann Dermatol Venereol; 2003 Apr; 130(4):489. PubMed ID: 12843869 [No Abstract] [Full Text] [Related]
46. How are drugs approved? Part 3. The stages of drug development. Howland RH J Psychosoc Nurs Ment Health Serv; 2008 Mar; 46(3):17-20. PubMed ID: 18416270 [TBL] [Abstract][Full Text] [Related]
47. Fomivirsen approved for CMV retinitis. Roehr B J Int Assoc Physicians AIDS Care; 1998 Oct; 4(10):14-6. PubMed ID: 11365956 [TBL] [Abstract][Full Text] [Related]
48. [Fluocortin butyl in various dermatoses in childhood]. Nemelka O; Occella C; Schiazza L; Persi A; Rampini E G Ital Dermatol Venereol; 1983; 118(1):VII-X. PubMed ID: 6358002 [No Abstract] [Full Text] [Related]
49. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Alper K; Schwartz KA; Kolts RL; Khan A Biol Psychiatry; 2007 Aug; 62(4):345-54. PubMed ID: 17223086 [TBL] [Abstract][Full Text] [Related]
50. The United States Food and Drug Administration and noninferiority margins in clinical trials of antimicrobial agents. Powers JH; Ross DB; Brittain E; Albrecht R; Goldberger MJ Clin Infect Dis; 2002 Mar; 34(6):879-81. PubMed ID: 11850875 [No Abstract] [Full Text] [Related]
51. Trichloroacetic acid in dermatology of 1911. Kopera D; Holubar K Int J Dermatol; 1998 Mar; 37(3):205. PubMed ID: 9556109 [No Abstract] [Full Text] [Related]
53. The United States Food and Drug Administration and the end of antibiotics. Shlaes DM; Moellering RC Clin Infect Dis; 2002 Feb; 34(3):420-2. PubMed ID: 11774094 [No Abstract] [Full Text] [Related]
54. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process. Roden DM; Temple R Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869 [No Abstract] [Full Text] [Related]
55. Biosimilars in dermatology: starting with infliximab. Puig L Actas Dermosifiliogr; 2013 Apr; 104(3):175-80. PubMed ID: 23218608 [No Abstract] [Full Text] [Related]
56. Drug treatments for skin disease introduced in 2007. Skin Therapy Lett; 2008 Mar; 13(2):7-9. PubMed ID: 18373042 [TBL] [Abstract][Full Text] [Related]
57. FDA evaluates accelerated approval process. Food and Drug Administration. Common Factor; 1995 Apr; (no 10):18. PubMed ID: 11362343 [TBL] [Abstract][Full Text] [Related]
58. Off-label uses of biologics in dermatology: interferon and intravenous immunoglobulin (part 1 of 2). Smith DI; Swamy PM; Heffernan MP J Am Acad Dermatol; 2007 Jan; 56(1):e1-54. PubMed ID: 17190617 [TBL] [Abstract][Full Text] [Related]